Bliss GVS Pharma
Ticker > Company >

Bliss GVS Pharma share price

Bliss GVS Pharma Ltd.

NSE: BLISSGVS BSE: 506197 SECTOR: Pharmaceuticals & Drugs  73.91 K   234   25

151.45
-0.20 (-0.13%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 153.5

Today's Low

₹ 150.65

52 Week High

₹ 190.65

52 Week Low

₹ 105.05

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 1599.46 Cr.

Enterprise Value

₹ 1479.36 Cr.

No. of Shares

10.56 Cr.

P/E

22.66

P/B

1.49

Face Value

₹ 1

Div. Yield

0.33 %

Book Value (TTM)

₹  101.64

CASH

₹ 171.11 Cr.

DEBT

₹ 51.01 Cr.

Promoter Holding

35.44 %

EPS (TTM)

₹  6.69

Sales Growth

10.2%

ROE

6.78 %

ROCE

9.31%

Profit Growth

36.18 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Bliss GVS Pharma Ltd.

Alain Gvither Lonart Rectol PARAFEN Vomitin Slipizem tacy Imazole Ecozole Vagikit Lofnac Comit Zinvite Clomain Alvite FUNBACT SOAP TODAY Instant Head Sanitizer SOFTNESS Mosquito Repellant Cream VAGID Dusting powder ALLSOFT

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year10.2%
3 Year1.59%
5 Year8.59%

Profit Growth

1 Year36.18%
3 Year-9.38%
5 Year-5.67%

ROE%

1 Year6.78%
3 Year7.25%
5 Year8.58%

ROCE %

1 Year9.31%
3 Year9.85%
5 Year11.25%

Debt/Equity

0.0485

Price to Cash Flow

16.45

Interest Cover Ratio

15.3035

CFO/PAT (5 Yr. Avg.)

1.10661150915657

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 35.44 0.00
Mar 2025 35.29 0.00
Dec 2024 35.10 0.00
Sep 2024 34.82 0.00
Jun 2024 34.90 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 15.3035.
  • Company’s PEG ratio is 0.641743050226794.
  • Company has a healthy liquidity position with current ratio of 6.1635.
  • The company has a good cash flow management; CFO/PAT stands at 1.10661150915657.

 Limitations

  • The company has shown a poor profit growth of -9.37521298963219% for the Past 3 years.
  • The company has shown a poor revenue growth of 1.5904151519226% for the Past 3 years.
  • Company has a poor ROE of 7.25063333333333% over the past 3 years.
  • Company has high debtor days of 226.4167.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 148.96 182.65 179.59 156 163.36
Total Expenditure 122.22 157.27 153.86 142.27 130.6
Operating Profit 26.74 25.38 25.73 13.73 32.77
Other Income 6.84 8.35 11.66 9.36 10.59
Interest 1.17 3.45 0.67 1.3 5.11
Depreciation 6.26 6.4 6.96 7.44 7.69
Exceptional Items 0 0 0 0 0
Profit Before Tax 26.15 23.89 29.77 14.36 30.56
Tax 6.73 6.85 8.72 2.91 9.51
Profit After Tax 19.42 17.04 21.05 11.45 21.05
Adjusted EPS (Rs) 1.85 1.62 2 1.09 2

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 465.51 636.36 598.34 605.46 667.2
Total Expenditure 374.05 527.16 508.18 498.29 575.62
Operating Profit 91.46 109.2 90.16 107.17 91.59
Other Income 19.41 32.63 50.77 33.5 36.22
Interest 5.92 4.32 10.06 5.81 6.58
Depreciation 13.76 13.85 15.17 23.52 27.05
Exceptional Items 0 2.75 0 -41.09 0
Profit Before Tax 91.19 126.4 115.69 70.26 94.17
Tax 23.69 33.74 30.21 19.61 25.2
Net Profit 67.5 92.66 85.48 50.64 68.97
Adjusted EPS (Rs.) 6.54 8.94 8.21 4.84 6.55

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 10.31 10.37 10.42 10.47 10.54
Total Reserves 745.33 841.06 926.58 977.97 1048.1
Borrowings 32.49 23.22 40.69 35.1 19.67
Other N/C liabilities 11.38 12.48 8.65 7.73 7.74
Current liabilities 146.11 192.83 153.36 114.89 124.55
Total Liabilities 945.62 1079.96 1139.69 1146.16 1210.6
Assets
Net Block 174.1 224.31 324.82 329.95 367.89
Capital WIP 2.39 22.15 2.8 7.83 20.58
Intangible WIP 0 0 0 0 0
Investments 18.3 18.26 18.26 18.69 18.69
Loans & Advances 11.35 22.44 17.18 14.27 16.24
Other N/C Assets 62.84 1.05 46.99 3.19 19.52
Current Assets 676.64 791.74 729.65 772.23 767.69
Total Assets 945.62 1079.96 1139.69 1146.16 1210.6
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 91.19 123.66 115.69 111.34 94.17
Adjustment 41.14 35.1 41.42 44.25 56.44
Changes in Assets & Liabilities -42.64 -14.23 -75.58 -44.08 -23.08
Tax Paid -22.72 -30.47 -37.72 -29.34 -30.33
Operating Cash Flow 66.97 114.05 43.81 82.17 97.21
Investing Cash Flow -61.62 -92.28 -12.97 -65.84 -77.73
Financing Cash Flow -11.67 -12.62 -26.05 -20.76 -26.71
Net Cash Flow -6.33 9.14 4.79 -4.43 -7.23

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 34.90 34.82 35.10 35.29 35.44
gagan harsh sharma - - - - 0.19
narsimha shibroor kamath 30.47 30.39 30.69 30.78 30.75
punita sharma 0.02 0.02 0.02 0.02 0.02
ramadas vasudev kamath hu... - - 0.03 - 0.03
shibroor gokuldas kamath 0.01 0.01 0.01 0.01 0.01
shruti vishal rao 2.01 2.01 2.00 2.00 2.00
vibha gagan sharma 2.36 2.35 2.35 2.44 2.44
ramadas vasudev kamath. 0.03 0.03 - 0.03 -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 65.10 65.18 64.90 64.71 64.56
arian investment limited 8.96 8.79 8.76 8.58 7.93
arjun gautam ashra . 4.81 4.80 4.79 4.79 4.79
coeus global opportunitie... - 1.77 1.76 1.76 1.76
gautam rasiklal ashra 2.83 2.81 2.83 2.83 2.83
gulbarga trading and inve... 5.57 5.55 5.53 5.53 5.53
investor education and pr... 2.38 2.38 2.37 2.45 2.44
life insurance corporatio... 6.58 6.56 6.55 6.55 6.54
llp 0.04 0.07 0.10 0.22 0.23
aspire emerging fund 1.34 - - - -
polus global fund 1.77 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit INFOMERIC
Credit CRISIL
Credit CRISIL
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Bliss GVS Pharma - Quaterly Results 29 Jul, 6:25 PM Bliss GVS Pharma - Quaterly Results 29 Jul, 6:25 PM Bliss GVS Pharma - Quaterly Results 29 Jul, 6:25 PM Bliss GVS Pharm informs about allotment of shares under ESOP 28 Jul, 5:06 PM Bliss GVS Pharma informs about closure of trading window 30 Jun, 1:29 PM Bliss GVS Pharma informs about disclosure 26 Jun, 11:19 AM Bliss GVS Pharma informs about outcome of postal ballot 12 Jun, 5:13 PM Bliss GVS Pharma informs about disclosure 12 Jun, 2:13 PM Bliss GVS Pharma informs about allotment of shares 6 Jun, 5:36 PM Bliss GVS Pharma informs about disclosure 23 May, 5:22 PM Bliss GVS Pharma - Quaterly Results 12 May, 9:00 PM Bliss GVS Pharma - Quaterly Results 12 May, 9:00 PM Bliss GVS Pharma informs about disclosure 3 May, 10:59 AM Bliss GVS Pharma’s marketing & distribution partner gets USFDA’s final approval for Mesalamine Suppositories 15 Apr, 6:26 PM Bliss GVS Pharma informs about disclosure 21 Feb, 10:52 AM Bliss GVS Pharma - Quaterly Results 28 Jan, 7:32 PM Bliss GVS Pharma - Quaterly Results 28 Jan, 7:32 PM Bliss GVS Pharma informs about compliance certificate 23 Nov, 2:28 PM Bliss GVS Pharma informs about disclosure 7 Nov, 5:04 PM Bliss GVS Pharma informs about disclosure 30 Oct, 12:38 PM Bliss GVS Pharma - Quaterly Results 25 Oct, 12:00 PM Bliss GVS Pharma - Quaterly Results 25 Oct, 12:00 PM Bliss GVS Pharma - Quaterly Results 24 Jul, 2:17 PM Bliss GVS Pharma - Quaterly Results 24 Jul, 2:17 PM Bliss GVS Pharma - Quaterly Results 24 Jul, 2:17 PM Bliss Gvs Pharma informs about appointment of independent director 22 Jun, 4:28 PM Bliss GVS Pharma informs about appointment of independent director 22 Jun, 3:52 PM Bliss GVS Pharma - Quaterly Results 2 May, 9:56 PM Bliss GVS Pharma - Quaterly Results 2 May, 9:56 PM Bliss GVS Pharma - Quaterly Results 23 Jan, 11:36 PM Bliss GVS Pharma - Quaterly Results 23 Jan, 11:36 PM Bliss GVS Pharma - Quaterly Results 1 Nov, 8:35 PM Bliss GVS Pharma - Quaterly Results 1 Nov, 8:35 PM Bliss GVS Pharma - Quaterly Results 1 Aug, 5:44 PM Bliss GVS Pharma - Quaterly Results 1 Aug, 5:44 PM Bliss Gvs Pharma informs about AGM outcome 19 Jul, 5:19 PM Bliss GVS Pharma gets EIR for Palghar manufacturing unit 15 Jun, 4:09 PM Bliss Gvs Pharma informs about book closure 12 May, 2:58 PM Bliss GVS Pharma - Quaterly Results 11 May, 10:48 PM Bliss GVS Pharma - Quaterly Results 11 May, 10:48 PM USFDA conducts inspections at Bliss GVS Pharma’s manufacturing unit in Palghar 20 Mar, 11:59 AM Bliss GVS Pharma informs about issuance of duplicate share certificate 18 Mar, 11:51 AM Bliss GVS Pharma informs about disclosure 1 Mar, 12:14 PM Bliss Gvs Pharma informs about disclosure 20 Feb, 3:00 PM Bliss GVS Pharma - Quaterly Results 24 Jan, 9:08 PM Bliss GVS Pharma - Quaterly Results 24 Jan, 9:08 PM BLISS GVS Pharma informs about outcome of board meeting 30 Dec, 5:16 PM Bliss GVS Pharma informs about loss of share certificate 17 Dec, 3:28 PM Bliss GVS Pharma - Quaterly Results 7 Nov, 8:05 PM Bliss GVS Pharma - Quaterly Results 7 Nov, 8:05 PM

Bliss GVS Pharma Stock Price Analysis and Quick Research Report. Is Bliss GVS Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Bliss GVS Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Bliss GVS Pharma has a PE ratio of 22.7763649962603 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Bliss GVS Pharma has ROA of 5.8528% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Bliss GVS Pharma has a Current ratio of 6.1635.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Bliss GVS Pharma has a ROE of 6.7847%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Bliss GVS Pharma has a Debt to Equity ratio of 0.0485 which means that the company has low proportion of debt in its capital.

  • Sales growth: Bliss GVS Pharma has reported revenue growth of 10.198% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Bliss GVS Pharma for the current financial year is 13.7267638742299%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Bliss GVS Pharma is Rs 0.5 and the yield is 0.3297%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Bliss GVS Pharma is Rs 6.685. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Bliss GVS Pharma in Ticker for free. Also, one can get the intrinsic value of Bliss GVS Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Bliss GVS Pharma FAQs

Q1. What is Bliss GVS Pharma share price today?
Ans: The current share price of Bliss GVS Pharma is Rs 152.26.

Q2. What is the market capitalisation of Bliss GVS Pharma?
Ans: Bliss GVS Pharma has a market capitalisation of Rs 1608.010581972 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Bliss GVS Pharma?
Ans: The PE ratio of Bliss GVS Pharma is 22.7763649962603 and the P/B ratio of Bliss GVS Pharma is 1.49803079690004, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Bliss GVS Pharma share?
Ans: The 52-week high share price of Bliss GVS Pharma is Rs 190.97, and the 52-week low share price of Bliss GVS Pharma is Rs 106.04.

Q5. Does Bliss GVS Pharma pay dividends?
Ans: Currently, Bliss GVS Pharma pays dividends. Dividend yield of Bliss GVS Pharma is around 0.3297%.

Q6. What are the face value and book value of Bliss GVS Pharma shares?
Ans: The face value of Bliss GVS Pharma shares is Rs 1, while the book value per share of Bliss GVS Pharma is around Rs 101.6401. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Bliss GVS Pharma?
Ans: Bliss GVS Pharma has a total debt of Rs 51.0089 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Bliss GVS Pharma?
Ans: The ROE of Bliss GVS Pharma is 6.7847% and ROCE of Bliss GVS Pharma is 9.3131%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Bliss GVS Pharma a good buy for the long term?
Ans: The Bliss GVS Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Bliss GVS Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Bliss GVS Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Bliss GVS Pharma’s financials?
Ans: You can review Bliss GVS Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Bliss GVS Pharma

Bliss GVS Pharma ABC Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Bliss GVS Pharma Limited is a leading pharmaceutical company that offers a range of products across various therapeutic segments such as antiviral, anti-malarial, antibiotic, anti-tuberculosis, and more. The company has a strong presence in both domestic and international markets with a focus on Africa, Asia, and CIS countries. With a commitment to providing high-quality, affordable healthcare solutions, Bliss GVS has become a trusted name in the pharmaceutical industry.

Bliss GVS Pharma Limited - Share Price

The share price of Bliss GVS Pharma Limited has been performing well in the past few quarters. It is an attractive option for long-term investors who are looking to invest in a growing pharmaceutical company. Our pre-built screening tools provide a detailed analysis of the share price, including trends, key market indicators, and other factors that can impact the stock's performance.

Bliss GVS Pharma Limited - Balance Sheet

The balance sheet of Bliss GVS Pharma Limited provides an overview of the company's financial health. Our premium features allow fair value calculation using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. The financial statements can be downloaded from our website and show a healthy financial position for the company.

Bliss GVS Pharma Limited - Annual Report

The annual report of Bliss GVS Pharma Limited provides a comprehensive overview of the company's financial performance over the year. It includes information about the company's operations, strategy, and future plans. The annual report is available for download on our website.

Bliss GVS Pharma Limited - Dividend

Bliss GVS Pharma Limited has been consistently paying dividends to its shareholders. The company has a track record of stable and increasing dividends, making it an attractive option for investors looking for a steady income stream. Our pre-built screening tools provide a detailed analysis of the company's dividend history and future prospects.

Bliss GVS Pharma Limited - Quarterly Result

The quarterly result of Bliss GVS Pharma Limited provides an update on the company's financial performance for the past quarter. Our premium features allow fair value calculation using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. The financial statements for the quarter can be downloaded from our website.

Bliss GVS Pharma Limited - Stock Price

The stock price of Bliss GVS Pharma Limited has been performing well in the past few quarters. It is an attractive option for long-term investors who are looking to invest in a growing pharmaceutical company. Our pre-built screening tools provide a detailed analysis of the stock price, including trends, key market indicators, and other factors that can impact the stock's performance.

Bliss GVS Pharma Limited - Price Chart

The price chart of Bliss GVS Pharma Limited provides a visual representation of the company's stock price over time. It can be used to identify trends, patterns, and key market indicators that can impact the stock's performance. Our pre-built screening tools include price charts that can be customized to suit individual investment needs.

Bliss GVS Pharma Limited - News

Our website provides up-to-date news on Bliss GVS Pharma Limited. This includes news about the company's operations, financial performance, new product launches, and other key developments. Investors can stay informed about the company's latest news and announcements through our website.

Bliss GVS Pharma Limited - Concall Transcripts

The concall transcripts of Bliss GVS Pharma Limited provide a detailed overview of the company's operations, financial performance, and other key developments. They can be downloaded from our website and provide valuable insights for long-term investors.

Bliss GVS Pharma Limited - Investor Presentations

The investor presentations of Bliss GVS Pharma Limited provide a comprehensive overview of the company's operations, strategy, and future plans. They can be downloaded from our website and provide valuable insights for long-term investors.

Bliss GVS Pharma Limited - Promoters

The promoters of Bliss GVS Pharma Limited are a key part of the company's success. They bring expertise, experience, and vision to the company, driving its growth and development. Our pre-built screening tools provide information about the company's promoters and their contribution to the company's success.

Bliss GVS Pharma Limited - Shareholders

The shareholders of Bliss GVS Pharma Limited are a key part of the company's success. They provide the necessary capital and support to drive the company's growth and development. Our pre-built screening tools provide information about the company's shareholders and their contributions to the company's success.

Note: This content is for information purposes only and does not constitute investment advice. The content is not intended to provide tax, legal, or investment advice or recommendations. The information contained herein is accurate to the best of our knowledge, but we make no guarantees that it is accurate or complete. Investors should conduct their own due diligence before making any investment decisions.

Bliss GVS Pharma Balance Sheet Analysis

Bliss GVS Pharma Equity and Liabilities Growth

Over the past five years, the equity and liabilities of Bliss GVS Pharma have shown a consistent growth pattern. From March 2020 to March 2024, the share capital slightly increased from Rs Cr. 10.31 to Rs Cr. 10.47. Total reserves surged from Rs Cr. 672.63 to Rs Cr. 977.97, indicating a strong retention of earnings and reinvestment in the company.

Bliss GVS Pharma Debt Management

The borrowings of Bliss GVS Pharma demonstrated a fluctuating trend but overall decreased from Rs Cr. 35.55 in March 2020 to Rs Cr. 35.10 by March 2024, showing the company's effective debt management strategies over the years.

Bliss GVS Pharma Asset Growth

Bliss GVS Pharma's total assets have been consistently growing from Rs Cr. 855.11 in March 2020 to Rs Cr. 1,148.44 by March 2024. The net block and current assets have significantly contributed to the asset base, indicating a solid foundation and operational strength.

Company Name's Strategic Investments

The company's strategic focus on investments remained prudent with a slight growth from Rs Cr. 19 in March 2020 to Rs Cr. 18.69 in March 2024. This stability in investments showcases the company's cautious approach towards portfolio management.

This data is an analysis for the Standalone Balance sheet of the company. Alongside monitoring Bliss GVS Pharma, investors are encouraged to explore various sectors and opportunities in IPOs for a diversified investment portfolio.

Read More
X